Physician profile
Leonard Kassis
NPI 1659547818
$3,666.30
in general payments reported to CMS, 2019-2025
33 companies · $658 in 2025
The $658 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $410 · 2021: $389 · 2022: $389 · 2023: $357 · 2024: $917 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $821.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $353.13 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $348.79 | 2019-2025 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $266.76 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Daiichi Sankyo INC. | $256.41 | 2020-2023 | Injectafer |
| Pfizer INC. | $229.30 | 2021-2025 | |
| Lilly USA, LLC | $182.97 | 2022-2025 | Zepbound, Mounjaro, Emgality |
| Exact Sciences Corporation | $169.72 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $126.20 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $102.32 | 2019-2025 | Veozah |
| Amgen INC. | $95.20 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Inspire Medical Systems, INC. | $85.76 | 2024-2025 | Inspire |
| Sanofi Pasteur INC. | $81.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $53.75 | 2020-2022 | |
| Lundbeck LLC | $51.09 | 2024-2025 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $39.37 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.88 | 2019 | |
| Abbott Laboratories | $33.78 | 2021-2022 | |
| Globus Medical, INC. | $33.65 | 2025 | Senza |
| Nevro Corp. | $33.02 | 2024 | Senza |
| Csl Behring | $33.00 | 2025 | Haegarda |
| Seqirus USA INC | $32.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $27.27 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $27.04 | 2019 | |
| Optinose US, INC. | $24.74 | 2024 | |
| Boston Scientific Corporation | $18.74 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.63 | 2022 | |
| Ibsa Pharma INC. | $16.65 | 2021 | |
| Dynavax Technologies Corporation | $14.94 | 2023 | Heplisav-B |
| Horizon Therapeutics Plc | $14.53 | 2019 | |
| Genentech USA, INC. | $13.65 | 2020 | |
| Amarin Pharma, INC. | $13.33 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Kassis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.